Article
News briefing: FDA lifts a hold on Poseida study; Decibel adopts 2-AAV approach to hearing loss; As
Rating:
0.0
Views:
117
Likes:
1
Library:
1
A little more than 2 months ago, shares of newly public Poseida Therapeutics $PSTX cratered after the biotech reported that a patient death had spurred the FDA to drop a full hold on its lead cancer drug. This morning we learned that regulators lifted the hold, but details are sparse.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value